<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01213498</url>
  </required_header>
  <id_info>
    <org_study_id>EBP-FHC-2010-2</org_study_id>
    <nct_id>NCT01213498</nct_id>
  </id_info>
  <brief_title>The Effects of Atorvastatin on the Nitric Oxide-system in Patients With Non-diabetic Nephropathy</brief_title>
  <acronym>STAN</acronym>
  <official_title>The Effects of Atorvastatin on the Nitric Oxide-system in Patients With Non-diabetic Nephropathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Erling Bjerregaard Pedersen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Regional Hospital Holstebro</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      It has been documented that statin reduce mortality and morbidity in patients with
      cardiovascular disease. This effect can partly be related to a reduction in cholesterol
      levels in blood. Nitric oxide (NO) production is reduced in several chronic diseases such as
      nephropathy, diabetes and hypertension. The purpose of this study is to investigate the
      effect of Atorvastatin treatment on the NO-system measuring renal and cardiovascular
      variables in patients witk chronic kidney disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects will be examined on two examination days. 4 days prior to each examination day
      subjects are treated with either atorvastatin or placebo. During treatment periods subject
      are given a standardized diet.

      On the examination days subject are given L-NMMA(L-NG-monomethyl Arginine citrate), a NO
      inhibitor, 6 mg bolus infusion followed by continuous 4 mg/kg/hr infusion for 1 hour. Renal
      function, central hemodynamic and vasoactive hormones are evaluated prior, during and after
      L-NMMA infusion.

      Renal function is measured by renal clearance of 51Chromium-EDTA and urinary sodium,
      potassium and albumin concentration. Urinary excretion of protein from NCC, NKCC and ENaC
      will be measured to evaluate channel activity in the nephron.

      Central blood pressure, pulse wave analysis, and augmentation index are measured using
      SphygmoCorÂ® from Atcor.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2010</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <primary_completion_date type="Actual">January 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Fractional excretion of sodium (FeNa)</measure>
    <time_frame>5 days treatment</time_frame>
    <description>Fractional excretion of urinary sodium before, during and after L-NMMA infusion</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Systolic blood pressure</measure>
    <time_frame>5 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma renin concentration</measure>
    <time_frame>5 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Arterial stiffness (Pulse wave velocity)</measure>
    <time_frame>5 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diastolic blood pressure</measure>
    <time_frame>5 day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Augmentation Index</measure>
    <time_frame>5 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary albumin excretion</measure>
    <time_frame>5 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary excretion of protein from sodium channels such as the NaCl cotransporter (NCC), the Na-K-Cl cotransporter (NKCC) and the epithelial sodium channel (ENaC)</measure>
    <time_frame>5 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>plasma aldosterone concentration</measure>
    <time_frame>5 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary Aquaporin 2(u-AQP2) excretion</measure>
    <time_frame>5 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>atrial natriuretic peptide (ANP) concentration</measure>
    <time_frame>5 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Brain natriuretic peptide concentration</measure>
    <time_frame>5 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Nephropathy</condition>
  <condition>Cardiovascular Diseases</condition>
  <arm_group>
    <arm_group_label>Atorvastatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Unikalk</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin</intervention_name>
    <description>Zarator, 80 mg pr. day for 5 days</description>
    <arm_group_label>Atorvastatin</arm_group_label>
    <other_name>Zarator</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Unikalk</intervention_name>
    <description>1 tablet Unikalk pr day for 5. days</description>
    <arm_group_label>Unikalk</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and women

          -  minimum 20 years

          -  Chronic Kidney disease

          -  Estimated GFR (eGFR) between 30 and 90 ml/min

        Exclusion Criteria:

          -  Nephrotic Syndrome

          -  Diabetes mellitus

          -  Anamnestic or clinical signs of significant heart, lung, lever, kidney, thyroid and
             brain disease

          -  Neoplastic disease

          -  Alcohol abuse,

          -  Drug abuse

          -  Pregnancy or nursing

          -  Blood donation within a month before examination

          -  Hgb &lt; 6,0
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Medicinsk Forskning, Regionshospitalet Holstebro</name>
      <address>
        <city>Holstebro</city>
        <zip>7500</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 19, 2010</study_first_submitted>
  <study_first_submitted_qc>October 1, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 4, 2010</study_first_posted>
  <last_update_submitted>August 19, 2015</last_update_submitted>
  <last_update_submitted_qc>August 19, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 21, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Regional Hospital Holstebro</investigator_affiliation>
    <investigator_full_name>Erling Bjerregaard Pedersen</investigator_full_name>
    <investigator_title>professor, chief physician</investigator_title>
  </responsible_party>
  <keyword>Nephrology</keyword>
  <keyword>Atorvastatin</keyword>
  <keyword>L-NMMA</keyword>
  <keyword>NO</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Kidney Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin Calcium</mesh_term>
    <mesh_term>Nitric Oxide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

